[go: up one dir, main page]

WO2007103572A3 - Extracorporeal removal of microvesicular particles - Google Patents

Extracorporeal removal of microvesicular particles Download PDF

Info

Publication number
WO2007103572A3
WO2007103572A3 PCT/US2007/006101 US2007006101W WO2007103572A3 WO 2007103572 A3 WO2007103572 A3 WO 2007103572A3 US 2007006101 W US2007006101 W US 2007006101W WO 2007103572 A3 WO2007103572 A3 WO 2007103572A3
Authority
WO
WIPO (PCT)
Prior art keywords
microvesicular particles
antigen
particles
medical devices
microvesicular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/006101
Other languages
French (fr)
Other versions
WO2007103572A2 (en
Inventor
Thomas Ichim
Richard H Tullis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aethlon Medical Inc
Original Assignee
Aethlon Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aethlon Medical Inc filed Critical Aethlon Medical Inc
Priority to EP19161598.8A priority Critical patent/EP3517151B1/en
Priority to EP07752778.6A priority patent/EP1993600B1/en
Priority to US12/282,152 priority patent/US8288172B2/en
Priority to CA2644855A priority patent/CA2644855C/en
Priority to ES07752778T priority patent/ES2736726T3/en
Publication of WO2007103572A2 publication Critical patent/WO2007103572A2/en
Anticipated expiration legal-status Critical
Publication of WO2007103572A3 publication Critical patent/WO2007103572A3/en
Priority to US13/623,662 priority patent/US9364601B2/en
Priority to US14/180,093 priority patent/US20140161810A1/en
Priority to US14/185,033 priority patent/US9707333B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/362—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed.
PCT/US2007/006101 2006-03-09 2007-03-09 Extracorporeal removal of microvesicular particles Ceased WO2007103572A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP19161598.8A EP3517151B1 (en) 2006-03-09 2007-03-09 Extracorporeal removal of microvesicular particles
EP07752778.6A EP1993600B1 (en) 2006-03-09 2007-03-09 Extracorporeal removal of microvesicular particles
US12/282,152 US8288172B2 (en) 2006-03-09 2007-03-09 Extracorporeal removal of microvesicular particles
CA2644855A CA2644855C (en) 2006-03-09 2007-03-09 Extracorporeal removal of microvesicular particles
ES07752778T ES2736726T3 (en) 2006-03-09 2007-03-09 Extracorporeal removal of microvesicular particles
US13/623,662 US9364601B2 (en) 2006-03-09 2012-09-20 Extracorporeal removal of microvesicular particles
US14/180,093 US20140161810A1 (en) 2006-03-09 2014-02-13 Extracorporeal removal of microvesicular particles
US14/185,033 US9707333B2 (en) 2006-03-09 2014-02-20 Extracorporeal removal of microvesicular particles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78094506P 2006-03-09 2006-03-09
US60/780,945 2006-03-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/282,152 A-371-Of-International US8288172B2 (en) 2006-03-09 2007-03-09 Extracorporeal removal of microvesicular particles
US13/623,662 Division US9364601B2 (en) 2006-03-09 2012-09-20 Extracorporeal removal of microvesicular particles

Publications (2)

Publication Number Publication Date
WO2007103572A2 WO2007103572A2 (en) 2007-09-13
WO2007103572A3 true WO2007103572A3 (en) 2008-09-12

Family

ID=38475607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/006101 Ceased WO2007103572A2 (en) 2006-03-09 2007-03-09 Extracorporeal removal of microvesicular particles

Country Status (6)

Country Link
US (4) US8288172B2 (en)
EP (2) EP3517151B1 (en)
CA (2) CA3061952C (en)
DK (1) DK3517151T3 (en)
ES (2) ES2736726T3 (en)
WO (1) WO2007103572A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2353399C2 (en) 2003-01-17 2009-04-27 Этлон Медикал, Инк. Method of isolating virus from blood by lectin hemodialysis
EP3517151B1 (en) 2006-03-09 2021-04-21 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
US20100255514A1 (en) 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
US9186405B2 (en) 2007-08-16 2015-11-17 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
WO2009086203A2 (en) * 2007-12-27 2009-07-09 Aethlon Medical, Inc. Method and apparatus for increasing contaminant clearance rates during extracorporeal fluid treatment
ES2936256T3 (en) * 2008-02-01 2023-03-15 Massachusetts Gen Hospital Use of microvesicles in the diagnosis, and prognosis of diseases and medical conditions
US20110218512A1 (en) * 2008-06-03 2011-09-08 Aethlon Medical, Inc. Enhanced antiviral therapy methods and devices
US10545149B2 (en) 2008-10-06 2020-01-28 Morehouse School Of Medicine Detection of HIV-related proteins in urine
US9487837B2 (en) 2008-10-06 2016-11-08 Morehouse School Of Medicine Exosome-mediated diagnosis of hepatitis virus infections and diseases
WO2010065765A2 (en) * 2008-12-04 2010-06-10 Aethlon Medical, Inc. Affinity capture of circulating biomarkers
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
WO2011031892A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
EP2591359B1 (en) * 2010-07-07 2017-03-01 Aethlon Medical Inc Methods for quantifying exosomes
US20120046231A1 (en) * 2010-08-23 2012-02-23 Andre Francis Palmer Composition and process for synthesizing polymerized human serum albumin for applications in transfusion medicine
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2638057B1 (en) 2010-11-10 2019-03-06 Exosome Diagnostics, Inc. Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
WO2012112865A2 (en) * 2011-02-17 2012-08-23 Cornell University Compositions and methods to prevent cell transformation and cancer metastasis
EP2495025A1 (en) 2011-03-04 2012-09-05 Fresenius Medical Care Deutschland GmbH Filter for the removal of micro-vesicles from biological fluids, methods and devices using such a filter
ES2744589T3 (en) * 2011-05-11 2020-02-25 Exosome Diagnostics Inc Nucleic acid extraction from heterogeneous biological materials
US9549953B2 (en) * 2011-12-08 2017-01-24 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
DE102012019088A1 (en) * 2012-09-28 2014-04-03 Orthogen Ag Antibacterial drug preparations
KR101933621B1 (en) 2012-09-28 2018-12-28 삼성전자주식회사 Compositions and kits for isolating a vesicle, and methods for isolating the vesicle using the same
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
EP2735359B1 (en) 2012-11-26 2017-02-08 Gambro Lundia AB Integrated device for liver support systems
PL2735326T3 (en) 2012-11-26 2017-08-31 Gambro Lundia Ab Liver support system
PL2735360T3 (en) 2012-11-26 2017-09-29 Gambro Lundia Ab Adsorber device combining beads and hollow fiber membranes
WO2014159662A1 (en) 2013-03-13 2014-10-02 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
WO2014140884A2 (en) * 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Methods and devices for removal of immunosuppressive ligands
CN105980615A (en) 2013-08-28 2016-09-28 卡里斯生命科学瑞士控股有限公司 Oligonucleotide probes and uses thereof
EP3099407B1 (en) * 2014-01-30 2020-02-05 Fresenius HemoCare Italia Srl Filtering device
CN106030304B (en) 2014-02-27 2018-02-06 得克萨斯大学体系董事会 For separating the method and composition of allochthon
US20170165334A1 (en) * 2015-12-11 2017-06-15 Tianxin Wang Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification
AU2016229076B2 (en) 2015-03-09 2022-01-20 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP3287137B1 (en) 2015-03-12 2021-05-05 Mitsui Chemicals, Inc. Method for disrupting exosomes, exosome disruption kit, and method for separating exosomes derived from normal cells
IL256634B2 (en) 2015-06-29 2025-08-01 Caris Science Inc Therapeutic oligonucleotides
US10941176B2 (en) 2015-07-28 2021-03-09 Caris Science, Inc. Therapeutic oligonucleotides
EP3246703A1 (en) 2016-05-20 2017-11-22 Unicyte EV AG Method and kit for capturing extracellular vesicles (evs) on a solid surface
WO2018071681A1 (en) 2016-10-13 2018-04-19 Vbc Holdings Llc Cancer stem cell exosomes
US11899024B2 (en) 2017-07-12 2024-02-13 Exosome Diagnostics, Inc. Treatment and diagnosis of parkinson's disease using isolated and enriched populations of biofluid-derived extracellular vesicles
PL3685165T3 (en) 2017-09-18 2022-08-08 Santersus Ag Method and device for purification of blood from circulating cell free dna
CN111386122A (en) * 2017-09-20 2020-07-07 分子听诊器公司 Method and system for detecting tissue condition
CA3086405A1 (en) 2018-01-05 2019-07-11 Path Ex, Inc. Device for the capture and removal of disease material from fluids
AU2019240901B2 (en) * 2018-03-30 2025-07-17 Exosomics S.p.A. Use of hollow fibers to obtain blood or a blood derivative impoverished from blood cells and platelets derived extracellular vesicles
AU2019362006A1 (en) 2018-10-17 2021-05-20 ImMutriX Therapeutics, Inc. Adsorption and binding of plasma molecules and particles to carbon
US12186472B2 (en) * 2019-03-06 2025-01-07 Gambro Lundia Ab Blood treatment device comprising alkaline phosphatase
JP2022538125A (en) * 2019-06-27 2022-08-31 バイオイミュネイト テクノロジーズ リミテッド Filters for removal of multiple sclerosis-associated T cells
CA3178687A1 (en) 2020-04-12 2021-10-21 Aethlon Medical, Inc. Devices and methods for treating a coronavirus infection and symptoms thereof
CN115768459A (en) 2020-04-14 2023-03-07 西托索尔本茨公司 Improving immune response and reducing immune paralysis by immunomodulating therapy
US11103628B1 (en) * 2020-04-29 2021-08-31 Orth Consulting, Llc Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide
WO2021221636A1 (en) * 2020-04-29 2021-11-04 Orth Consulting, Llc Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide
US10881781B1 (en) 2020-04-29 2021-01-05 Orth Consulting, Llc Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide
USD952157S1 (en) 2020-06-19 2022-05-17 Qualigen Inc. Whole blood treatment cartridge
EP4213909A1 (en) * 2020-09-21 2023-07-26 Belgian Volition SRL Device for inline monitoring of free nucleosomes in blood
US11224858B1 (en) 2020-10-01 2022-01-18 Immunicom, Inc. Reduced leaching of a ligand
IL301787A (en) * 2020-10-01 2023-05-01 Immunicom Inc Reduced filtration of ligand
US11319520B1 (en) 2021-09-21 2022-05-03 Upside Foods, Inc. Filter cake-based systems and methods for the cultivation of cells and cell biomass
US12053567B2 (en) 2021-12-27 2024-08-06 Santersus Ag Method and device for removal of circulating cell free DNA
CN119110725A (en) * 2022-04-06 2024-12-10 盖立复环球运营有限公司 Extracellular vesicle-depleted blood fraction
WO2024072901A1 (en) * 2022-09-28 2024-04-04 Sigyn Therapeutics, Inc. System and methods to enhance chemotherapy delivery and reduce toxicity
GB202405785D0 (en) * 2024-04-24 2024-06-05 Vesalic Ltd A method of suppressing a neurological disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064608A2 (en) * 2003-01-17 2004-08-05 Aethlon Medical, Inc. Method for removal of viruses from blood by lectin affinity hemodialysis
CA2453198A1 (en) * 2004-01-07 2005-07-07 Wei-Ping Min Quantification and generation of immune suppressive exosomes

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925152A (en) 1971-06-18 1975-12-09 Exploaterings Ab Tbf Virus separation
US4787974A (en) 1981-06-29 1988-11-29 Ambrus Clara M Blood purification
US4714556A (en) 1981-06-29 1987-12-22 Ambrus Clara M Blood purification
US4708713A (en) 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals
US5782792A (en) 1986-11-21 1998-07-21 Cypress Bioscience, Inc. Method for treatment of rheumatoid arthritis
US5041079A (en) 1987-12-04 1991-08-20 Kuraray Co., Ltd. Method for removing human immunodeficiency virus and/or its related compounds
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5268275A (en) * 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
JP3615785B2 (en) 1994-04-28 2005-02-02 テルモ株式会社 HIV and related material removal materials
ATE327258T1 (en) 1995-03-20 2006-06-15 Ko Okumura MONOCLONAL ANTIBODY REACTING SPECIFICALLY WITH THE FAS LIGAND AND METHOD FOR PRODUCING IT
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
WO1999067647A1 (en) * 1998-06-24 1999-12-29 Chen & Chen, Llc Multi-layer testing column
DE69929986T2 (en) 1998-08-31 2006-10-19 Ambrus, Julian L. METHOD FOR REMOVING HIV AND OTHER VIRUSES FROM BLOOD
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
GB9927320D0 (en) * 1999-11-18 2000-01-12 Chiron Spa Exosome separation
US7572631B2 (en) * 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6812023B1 (en) * 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
EP1417229B1 (en) * 2001-08-17 2011-06-15 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
CA2479021A1 (en) * 2002-03-14 2003-09-18 Anosys, Inc. Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
PL1720611T3 (en) * 2004-02-16 2010-09-30 Proteosys Ag Diagnostic marker for cancer
WO2005107802A2 (en) * 2004-04-30 2005-11-17 Biopheresis Technologies, Llc Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
US8021847B2 (en) * 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
JP2008505104A (en) * 2004-07-01 2008-02-21 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション Immunosuppressive exosomes
JP4029298B2 (en) * 2004-07-26 2008-01-09 大塚製薬株式会社 Method for removing sticky microvesicles
KR101290558B1 (en) 2004-07-30 2013-07-31 퓨리셀렉트 게엠베하 Device and method for isolating cells, bioparticles and/or molecules from liquids for use with animals, in biotechnology, (including biotechnological research) and medical diagnostics
CA2504279A1 (en) * 2005-04-15 2006-10-15 University Of Saskatchewan Materials and method of modulating the immune response using t helper-antigen presenting cells
CN101203234B (en) * 2005-05-13 2012-10-10 范斯坦医药研究院 Milk fat globule epidermal growth factor-factor Ⅷ and sepsis
US20090148460A1 (en) * 2005-07-08 2009-06-11 Alain Delcayre Exosome ligands, their preparation and uses
WO2007047907A2 (en) * 2005-10-14 2007-04-26 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
US20070122415A1 (en) * 2005-11-29 2007-05-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compound and method for suppressing retroviral replication
EP3517151B1 (en) * 2006-03-09 2021-04-21 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
AU2008207735B2 (en) * 2007-01-26 2013-10-03 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
US20090104649A1 (en) * 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
WO2009015357A1 (en) * 2007-07-25 2009-01-29 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
CA2706445C (en) * 2007-11-28 2019-07-23 Irx Therapeutics, Inc. Production of apoptosis-resistant t-lymphocytes for use in cancer therapy
ES2936256T3 (en) * 2008-02-01 2023-03-15 Massachusetts Gen Hospital Use of microvesicles in the diagnosis, and prognosis of diseases and medical conditions
CN102301002A (en) * 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 Methods and systems for determining phenotypes using exosomes
WO2010065765A2 (en) * 2008-12-04 2010-06-10 Aethlon Medical, Inc. Affinity capture of circulating biomarkers
SG177677A1 (en) * 2009-07-16 2012-02-28 Gen Hospital Corp Nucleic acid analysis
EP2507393A4 (en) * 2009-11-30 2013-05-01 Caris Life Sciences Luxembourg Holdings Methods and systems for isolating, storing, and analyzing vesicles
EA201201085A1 (en) * 2010-02-11 2013-05-30 Католиеке Иниверситейт Леувен PHOSPHOLIPID PROFILE AND CANCER
EP2591359B1 (en) * 2010-07-07 2017-03-01 Aethlon Medical Inc Methods for quantifying exosomes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064608A2 (en) * 2003-01-17 2004-08-05 Aethlon Medical, Inc. Method for removal of viruses from blood by lectin affinity hemodialysis
CA2453198A1 (en) * 2004-01-07 2005-07-07 Wei-Ping Min Quantification and generation of immune suppressive exosomes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FINN ET AL.: "Cancer Vaccines: Between the Idea and the Reality", NATURE REVIEWS IMMUNOLOGY, vol. 3, August 2003 (2003-08-01), pages 630 - 641, XP009133954 *
RAZ ET AL.: "Isolation of Plasma Membrane Fragments and Vesicles from Ascites Fluid of Lymphoma-Bearing Mice and Their Possible Role in the Escape Mechanism of Tumors from Host Immune Rejection", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 4, 1978, pages 53 - 59, XP008131030 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes

Also Published As

Publication number Publication date
ES2880460T3 (en) 2021-11-24
DK3517151T3 (en) 2021-07-12
US20140166578A1 (en) 2014-06-19
WO2007103572A2 (en) 2007-09-13
EP3517151A1 (en) 2019-07-31
US20130015118A1 (en) 2013-01-17
ES2736726T3 (en) 2020-01-07
CA3061952C (en) 2022-07-19
CA2644855C (en) 2019-11-19
US9364601B2 (en) 2016-06-14
EP1993600B1 (en) 2019-04-24
EP1993600A4 (en) 2014-02-19
US9707333B2 (en) 2017-07-18
US8288172B2 (en) 2012-10-16
US20090304677A1 (en) 2009-12-10
CA2644855A1 (en) 2007-09-13
EP3517151B1 (en) 2021-04-21
EP1993600A2 (en) 2008-11-26
CA3061952A1 (en) 2007-09-13
US20140161810A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
WO2007103572A3 (en) Extracorporeal removal of microvesicular particles
WO2009156405A8 (en) Novel immunoadjuvant flagellin-based compounds and use thereof
WO2012044662A3 (en) Filter structure for removing contaminants from stream of fluid
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2015138357A3 (en) Compositions useful in treatment of otc deficency
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2011057225A3 (en) Self-assembled particles from zwitterionic polymers and related methods
WO2012027514A3 (en) Compositions and methods for cardiac therapy
EP2146097A4 (en) Centrifugal blower
MX2019000225A (en) Compositions and methods for treatment of autoimmune and other disease.
EP2173227A4 (en) Vacuum cleaner and method of controlling the same
WO2013055949A3 (en) Pyrazol-3-ones that activate pro-apoptotic bax
EP2530332A4 (en) Centrifugal compressor and cleaning method
WO2007101161A8 (en) Methods and compositions for the treatment of gastrointestinal disorders
EP4420518A3 (en) Compositions and methods of use thereof
WO2012073047A3 (en) Compositions and methods
EP2535598A4 (en) Centrifugal compressor using an asymmetric self-recirculating casing treatment
IL214749A0 (en) Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
WO2012024282A3 (en) 1,5-diphenyl-penta-1,4-dien-3-one compounds
WO2012065135A3 (en) Immunomodulatory compositions, methods and systems comprising immunogenic fragments of apob100
WO2013036610A3 (en) Compositions comprising mg53 and methods for the treatment and prevention of airway injury
WO2010056144A3 (en) Foxp3+ natural kiler t-cells and the treatment of immune related diseases
WO2008092099A8 (en) Compositions and methods for treating hematopoietic malignancies
EP2535596A4 (en) Centrifugal compressor using an asymmetric self-recirculating casing treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2644855

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 8139/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007752778

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12282152

Country of ref document: US